Efinaconazole

Systematic (IUPAC) name
(2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol
Clinical data
Trade names	Jublia, Clenafin
Licence data	US FDA:link
Legal status	CA: ℞-only US: ℞-only
Routes of administration	Topical
Pharmacokinetic data
Bioavailability	Unknown oral
Identifiers
CAS Number	164650-44-6
ATC code	D01AC19 (WHO)
PubChem	CID: 489181
ChemSpider	428538
ChEBI	CHEBI:82718 Y
Chemical data
Formula	C18H22F2N4O
Molecular mass	348.39 g/mol
SMILES C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
InChI InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1 Key:NFEZZTICAUWDHU-RDTXWAMCSA-N

Efinaconazole (trade names Jublia and Clenafin) is a triazole antifungal. It is approved for use in Canada and the USA as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail). Efinaconazole acts as a 14α-demethylase inhibitor.

In two clinical trials 17.8% and 15.2% of patients using Efinaconazole were cured, compared to 3.3% and 5.5% of patients using a placebo.

Efinaconazole is not especially effective, but it is currently the best topical treatment available, with cure rates two or three times better than the next best topical treatment, ciclopirox. It is considered a reasonable options for patients with mild cases, or patients who can not take oral treatment.

In 2014, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Jublia, the "first topical triazole approved for the treatment of onychomycosis of the toenails." According to Valeant Pharmaceuticals International Inc CEO J. Michael Pearson they acquired Jublia through their purchase of Dow Pharmaceutical Sciences in 2008.